What guidance did RCM Technologies's management provide for the next earnings period?

What is RCM Technologies's latest dividend and current dividend yield?

What is the market's earnings forecast for RCM Technologies next quarter?

What factors drove the changes in RCM Technologies's revenue and profit?

What does RCM Technologies do and what are its main business segments?

What were the key takeaways from RCM Technologies's earnings call?

What is RCM Technologies's gross profit margin?

What were the key takeaways from RCM Technologies’s earnings call?

- **Record Engineering Backlog**: $70M for 2026, up from $21M in 2024, driven by Energy Services.
- **Healthcare Growth**: 20.7% school revenue increase, new partnerships, and 2026 pipeline momentum.
- **Medical Cost Challenges**: $1.8M over budget YTD, with no immediate relief beyond 2026 measures.
- **Aerospace/Defense Surge**: 45% revenue growth, 110% EBITDA rise, and Bell Flight's Best New Supplier award.
- **AI and Digital Innovation**: Life Sciences AI compliance, predictive analytics, and 3D BIM in engineering.

**【Management Opening Remarks】**
- Kevin Miller provided standard disclaimers about forward-looking statements.
- Brad Vizi highlighted record 2026 engineering backlog and healthcare momentum, despite $1.8M in excess medical costs year-to-date.

**【CEO Business Unit Updates】**
- **Healthcare**: 20.7% growth in school revenue, new school partners, and broadened client roles. Anticipates 2026 benefits from a foreign recruitment pipeline.
- **Life Sciences**: AI-driven compliance streamlines protocols; dedicated engineering group and AI analytics for predictive forecasting.
- **Engineering**: Energy Services achieved $70M 2026 backlog, outpacing 2024's $21M. Aerospace/Defense saw 45% revenue growth, 49% gross profit increase, and 110% EBITDA rise.
- **Talent Attraction**: Increased qualified candidates, driven by brand strength and digital presence.

**【CFO Financial Commentary】**
- **Consolidated Results**: Q3 2025 gross profit up 8.8% to $19.4M; adjusted EBITDA $5.5M (-1.4% YoY). Healthcare gross profit +8.5%, Engineering +17.3% (record high).
- **Challenges**: $1.8M over budget medical claims; Q3 cash flow issues with 2 large clients.
- **Q4 Outlook**: Highest quarterly gross profit and EBITDA expected, with focus on 2026 backlog growth.

**【Q&A Highlights】**
- **Foreign Nurses**: 300+ nurses in pipeline, visa timeline uncertain; 50-60 potential arrivals if dates move 3-4 months.
- **Medical Costs**: $1.8M over budget YTD; 2026 cost reduction measures in early stages.
- **Engineering Growth**: Focus on Tier 1 utilities; interconnect projects for data centers.
- **Capital Allocation**: Share buybacks cautious; dividend consideration ongoing.
- **Talent Strategy**: Digital brand investment attracts top talent, especially in engineering and healthcare.

RCM Technologies, Inc. (RCMT) Q3 2025 Earnings Call Transcript

- **Record Financial Performance**: Q2 2025 gross profit ($22.3M) and EBITDA ($8.1M) hit 13-quarter highs, up 11.4% and 12.9% YoY. 
- **Engineering Surge**: Segment delivered record gross profit ($6.5M) despite margin volatility, driven by grid modernization and data center projects. 
- **Aerospace Outperformance**: Exceeded Q2 revenue targets by $3M, with 53 new hires and 8% sequential EBITDA growth. 
- **Health Care Momentum**: 21.1% school revenue growth and 15.4% gross profit expansion, with new contracts for 2025/26. 
- **Strategic Wins**: Gained market share in K-12 education and aerospace, winning clients from competitors. 
- **Cash Flow Update**: Q2 collections lagged due to school funding delays, but 80% of delayed payments resolved, with remainder expected in Q3. 
- **Dividend Potential**: Management open to dividend but prioritizing share buybacks and growth investments. 


**【Management Opening Remarks】**
- **Resilience and Growth**: Despite economic uncertainty, the company maintained strong performance across all segments, driven by its talent-aligned business model and brand equity. 
- **Market Expansion**: Inclusion in the Russell 2000 Growth Index highlights RCM's recognition as a growth-oriented company. 
- **Segment Highlights**: 
  - **Health Care Services Group**: Achieved 21.1% revenue growth in Q2 2025, with new school partnerships and wins over competitors. 
  - **Aerospace & Defense**: Exceeded Q2 revenue targets by $3M, with 53 new hires and sequential EBITDA growth of 8%. 
  - **Engineering**: Accelerated activity in grid modernization and data centers, with a focus on integrating advanced technologies. 
  - **Life Sciences**: Advanced AI-driven compliance solutions and expanded its Engineering Group to support pharma clients. 

**【CFO Financial Commentary】**
- **Overall Performance**: Q2 2025 saw 11.4% YoY growth in gross profit ($22.3M) and 12.9% YoY increase in adjusted EBITDA ($8.1M). 
- **Segment Breakdown**: 
  - **Health Care**: Gross profit up 15.4% YoY ($12.3M), with school revenue growing 21.1%. 
  - **Engineering**: Record gross profit ($6.5M) despite margin volatility, driven by fixed-price contracts. 
  - **Life Sciences**: Gross margin improved to 39.8% YoY, reflecting cost efficiency. 
- **Cash Flow**: Q2 collections lagged due to school funding delays, but 80% of delayed payments were resolved, with remaining amounts expected in Q3. 
- **Balance Sheet**: Strong free cash flow alignment with net income, no debt, and a focus on capital allocation for growth. 

**【Q&A Highlights】**
- **Engineering Growth**: Analysts noted Engineering's 8.8% YoY gross profit growth, driven by multiyear contracts and project execution improvements. Management emphasized quality over margin sensitivity. 
- **Health Care Expansion**: Focus remains on K-12, with 12 new school contracts for the 2025/26 year. Internal training programs (e.g., Philippines-based staff) support scalability. 
- **Dividend Consideration**: Management acknowledged the potential for a dividend but prioritized share buybacks and growth investments. 
- **Immigration Impact**: Nurse visa delays could constrain 2025/26 growth, but long-term demand for foreign nurses is expected to persist. 
- **Cash Collections**: Q2 receivables were temporary due to school funding cycles, with no risk of bad debt. 


RCM Technologies, Inc. (RCMT) Q2 2025 Earnings Call Transcript

- **Top Line Growth**: 7.9% YoY gross profit growth to $22.0M, driven by 16.7% school-based healthcare revenue expansion and 12.4% Engineering gross profit increase.
- **Profitability**: Adjusted EBITDA up 14.4% to $7.8M, EPS up 18.9% to $0.63. Aerospace EBITDA surged 247% YoY.
- **Cash Generation**: $16.7M operating cash flow, 23% DSO improvement, $12M debt reduction.
- **Key Growth Drivers**: AI/ML adoption in IT, grid modernization projects, and aerospace aftermarket contracts.
- **Share Buybacks**: 300K+ shares repurchased YTD, reducing outstanding shares by ~50% over 5 years.
- **Margin Outlook**: Engineering gross margin to normalize at 22-26%, healthcare margin stable at ~28%.


**【Brad Vizi - Business Overview】**
- **Healthcare Segment**: School-based revenue grew 16.7% YoY to $37.3M, driven by new school contracts and behavioral health expansion. Non-school revenue stabilized at $5.5M after strategic reduction of low-margin services. Offshore team efficiency enabled margin preservation despite volume growth.
- **Life Sciences & Data Solutions**: 40% gross profit margin and 23% NOI contribution from strong managed services. 6 new clients added in Q1 2025 across asset management, design engineering, and BPO payroll. IT industry AI/ML adoption accelerating with system deployments.
- **Engineering Segment**: 
  - **Energy Services**: Multiyear preferred partner agreements in grid modernization and data centers. Gross profit up 12.4% YoY to $6.2M, highest in company history. Nearshore/offshore scaling underway.
  - **Aerospace & Defense**: EBITDA up 247% YoY to $1M weekly run rate. 50 new hires in Q1, winning S1000D conversion contracts for long-term aftermarket work. 3 new clients added in supply chain manufacturing.
  - **Process & Industrial**: Ethanol plant expansion project to increase capacity by 20%. Lithium extraction pilot testing complete, equipment order scheduled for late 2025. RFQ activity up due to digital marketing improvements.
- **Share Repurchases**: 300K+ shares bought YTD, reducing outstanding shares by ~50% over 5 years. Maintaining clean balance sheet with $18.2M net debt.

**【Kevin Miller - Financial Results】**
- **Top Line**: Consolidated gross profit $22.0M (+7.9% YoY), highest in 12 quarters. Adjusted EBITDA $7.8M (+14.4% YoY), Adjusted EPS $0.63 (+18.9% YoY).
- **Segment Performance**: 
  - **Healthcare**: Gross profit $12.2M (+10.2% YoY), margin 28.2%. Nursing contracts slightly dilutive but offset by behavioral health growth.
  - **Engineering**: Gross profit $6.2M (+12.4% YoY), margin 19.2% (temporarily low due to construction pass-through revenue and Aerospace mix).
  - **IT/Life Sciences**: Gross profit $3.6M (-5.3% YoY), margin 39.7% (up 270bps YoY).
- **Liquidity**: DSO improved to 74 days (from 92 days Q4 2024), generating $16.7M cash flow. Net debt reduced by $12.0M to $18.2M.

**【Q&A Highlights】**
- **Policy Risk**: No direct impact on services business; focused on secular trends like AI adoption, grid modernization.
- **Gross Margin Volatility**: Engineering margin expected to normalize between 22-26% as construction pass-through revenue stabilizes. Healthcare margin stable with ~100% renewal rate.
- **Cash Flow Outlook**: Q4 2025 expected to be highest EBITDA quarter, driven by Aerospace backlog and Engineering project completions.


RCM (RCMT)-8 May 25-2025 Q1 Earnings call transcript

- **Health Care Dominance**: 17% YoY revenue growth driven by school-based behavioral health services expansion.\n- **Engineering Recovery**: Q4 2024 Engineering gross profit down 15% YoY due to canceled orders, but 2025 grid modernization projects poised to offset.\n- **Aerospace Growth**: 20% QoQ headcount increase in Q4, with new contracts to support 2025 EBITDA growth.\n- **Tax Rate Reset**: 2025 effective tax rate expected to drop to 26-29% (from 34% in Q4 2024).\n- **2025 Outlook**: Double-digit adjusted EBITDA growth target, with key drivers in school mental health, energy infrastructure, & defense subcontracting.\n

**【Brad Vizi: Business Unit Overview】**
- **Health Care Growth**: Q4 revenue increased 17% YoY to $34.9M, driven by behavioral health demand (1 in 5 children with mental health disorders). School district partnerships expanded with 3 new clients and pipeline for 2025.\n- **Engineering Expansion**: Energy Services secured large grid modernization projects in North America and Europe. RCM Europe won a second German utility client.\n- **Aerospace & Defense Momentum**: Headcount grew 20% QoQ in Q4, EBITDA up YoY. New multiyear contracts and MSAs will support 2025 growth.\n- **Life Sciences Digitization**: Shifting from traditional IT to AI/ML tools for process automation. Secured 3 new clients and renewed 3 managed services contracts.\n- **Thermal Kinetics Innovation**: $3.5M equipment order for ethanol plant expansion. Test center pilot for lithium facility in Q1 2025.\n
**【Kevin Miller: Financial Highlights】**\n- **Q4 2024 Results**:\n  - Gross Profit: $21.6M (flat YoY), Adjusted EBITDA: $6.3M (-30% YoY).\n  - Key Drag Factors: $900K from canceled industrial order & rework, $1.25M in medical costs, $450K legal fees.\n  - Health Care gross margin: 30.0% (vs. 29.8% Q4 2023).\n- **2025 Outlook**:\n  - Target DSO <80 (Q4 2024: 92).\n  - Adjusted EBITDA growth >10% QoQ, aiming for low double-digit growth.\n  - Effective tax rate expected to drop to 26-29% (Q4 2024: 34.0%).\n
**【Q&A Key Takeaways】**\n- **Tax Rate Normalization**: 2025 rate ~26-29% vs. 34% in Q4 2024 (due to one-time deferred tax adjustments).\n- **Government Policy Impact**: No direct DOGE-related effects; potential future tailwind from workforce realignment.\n- **One-Time Costs**: $900K loss from canceled order & rework; no political factors involved.\n- **Client Stability**: Aerospace/Defense contracts insulated as subcontractors to Tier 1s.\n- **Revenue Visibility**: 2025 pipeline includes new school districts, energy projects, & defense programs.\n

Actual									-0.4473	-0.08	-0.02	-0.15	0.08	0.11	0.24	0.34	0.62	0.57	0.3095	0.47	0.3678	0.47	0.71	0.53	0.56	0.44	0.49	0.63	0.69	0.42
Forecast									0.065	-0.13	-0.03	0.005	0.035	0.055	0	0.15	0.27	0.5	0.28	0.475	0.38	0.455	0.625	0.475	0.53	0.44	0.83	0.585	0.62	0.445
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-788.15%	+38.46%	+33.33%	-3100.00%	+128.57%	+100.00%	0.00%	+126.67%	+129.63%	+14.00%	+10.54%	-1.05%	-3.21%	+3.30%	+13.60%	+11.58%	+5.66%	0.00%	-40.96%	+7.69%	+11.29%	-5.62%

RCMT

RCMT fundamentals

RCMT Q3 2025 Earnings

Earnings Call

You can ask Aime

RCMT

RCMT fundamentals

RCMT Q3 2025 Earnings

Earnings Call

RCMT Earnings Call Summary for Q3/202511:30 AM on Nov 6, 2025

RCMT Earnings Call Summary for Q2/202511:30 AM on Aug 7, 2025

RCMT Earnings Call Summary for Q1/202510:30 AM on May 8, 2025

RCMT Earnings Call Summary for Q4/202411:30 AM on Mar 13, 2025

RCMT Earnings Call Summary for Q3/20241:00 PM on Nov 8, 2024

You can ask Aime